Here, CD161 is identified as a novel inhibitory receptor on bone marrow (BM) tissue resident memory CD8+ T cells (CD8+ TRM), known for their sustained presence and vital role in local immune surveillance in MM BM tumor microenvironments. Here, CD8A is linked to neoplasm.